81450 Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequenc

Name of the Procedure:

Targeted Genomic Sequence Analysis Panel for Hematolymphoid Neoplasms or Disorders (DNA and RNA analysis, 5-50 genes)

Summary

This procedure involves analyzing specific genes in your DNA and RNA to help diagnose and manage blood-related cancers and disorders. It focuses on a panel of 5 to 50 known genes associated with these conditions to detect abnormalities.

Purpose

The test is used to identify genetic mutations or changes associated with hematolymphoid cancers, such as leukemia or lymphoma. The goal is to inform diagnosis, guide treatment plans, and predict patient outcomes.

Indications

This test is recommended if:

• You have symptoms suggestive of hematolymphoid neoplasms, like unexplained weight loss, swollen lymph nodes, or abnormal blood counts.
• Your doctor suspects a genetic aspect to your disorder.
• There is a need to monitor disease progression or response to treatment.

Preparation

• No specific preparation is typically required.
• However, you may be advised to avoid certain medications that could affect blood samples.
• A routine blood test or biopsy may be performed before the procedure to collect relevant samples.

Procedure Description

1. Sample Collection: Blood or tissue sample is collected from the patient.
2. DNA/RNA Extraction: The genetic material is extracted from the sample.
3. Sequencing: Advanced technology is used to sequence the targeted genes.
4. Data Analysis: Bioinformatics tools analyze the genetic sequence data to identify variations.

Tools and Equipment:

• Blood collection needles or biopsy tools.
• Sequencing machines (e.g., Next-Generation Sequencing).
• Bioinformatics software.

Anesthesia:

• Not required for blood samples.
• Local anesthesia may be used for tissue biopsies.

Duration

• The sample collection takes about 10-30 minutes.
• Sequencing and analysis can take a few days to a few weeks.

Setting

• Usually performed in a hospital or specialized outpatient clinic equipped for genetic testing.

Personnel

• Pathologists, lab technicians, and geneticists.
• Nurses for sample collection.
• Possibly a radiologist if a biopsy is involved.

Risks and Complications

• Minor risks associated with blood draw or biopsy, such as bleeding, infection, or bruising.
• Rarely, inconclusive results may necessitate additional testing.

Benefits

• Precise identification of genetic mutations can lead to tailored treatment plans.
• Early detection and improved management of hematolymphoid neoplasms.
• Helps predict disease prognosis and response to treatment.

Recovery

• Typically no recovery time needed for blood sample collection.
• Biopsy sites may need minimal care and monitoring for a day or two.
• Follow-up appointments to discuss results and treatment options.

Alternatives

• Broader genetic testing panels or whole-genome sequencing.
• Cytogenetic testing (e.g., karyotyping).
• Pros and cons: Targeted panels are faster and more focused, while broader tests may provide a more comprehensive analysis but take longer and may be more costly.

Patient Experience

• Minimal discomfort during blood draw or biopsy.
• Brief post-procedure soreness if a biopsy was performed.
• Results discussion with your healthcare provider to determine next steps in your care plan.
• Pain management strategies will be provided if needed, especially post-biopsy.